09/108 673
2 of 11

Search Results - Record(s) 1 through 38 of 38 returned.

1. Document ID: US 6013522 A
Entry 1 of 38
File: USPT
Jan 11, 2000

US-PAT-NO: 6013522
DOCUMENT-IDENTIFIER: US 6013522 A

TITLE: Antisense inhibition of human Smad1 expression

DATE-ISSUED: January 11, 2000

INVENTOR-INFORMATION:
NAME | CITY | STATE | ZIP CODE | COUNTRY
Monia; Brett P. | La Costa | CA | N/A | N/A
Cowsert; Lex M. | Carlsbad | CA | N/A | N/A

US-CL-CURRENT: 435/375; 435/325, 435/366, 435/455, 435/6, 435/91.1, 536/23.1, 536/24.31, 536/24.33, 536/24.5

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of Smad1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad1. Methods of using these compounds for modulation of Smad1 expression and for treatment of diseases associated with expression of Smad1 are provided.
20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

2. Document ID: US 6013788 A
Entry 2 of 38
File: USPT
Jan 11, 2000

US-PAT-NO: 6013788
DOCUMENT-IDENTIFIER: US 6013788 A

TITLE: Antisense modulation of Smad3 expression

DATE-ISSUED: January 11, 2000

INVENTOR-INFORMATION:
NAME | CITY | STATE | ZIP CODE | COUNTRY
Monia; Brett P. | La Costa | CA | N/A | N/A
Cowsert; Lex M. | Carlsbad | CA | N/A | N/A

US-CL-CURRENT: 536/24.5; 435/325, 435/375, 435/6, 435/91.1, 435/91.31, 536/23.1, 536/23.2, 536/24.3, 536/24.33

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of Smad3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad3. Methods of using these compounds for modulation of Smad3 expression and for treatment of diseases associated with expression of Smad3 are provided.
20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

3. Document ID: US 6013787 A
Entry 3 of 38
File: USPT
Jan 11, 2000

US-PAT-NO: 6013787
DOCUMENT-IDENTIFIER: US 6013787 A

TITLE: Antisense modulation of Smad4 expression

DATE-ISSUED: January 11, 2000

INVENTOR-INFORMATION:
NAME | CITY | STATE | ZIP CODE | COUNTRY
Monia; Brett P. | La Costa | CA | N/A | N/A
Cowsert; Lex M. | Carlsbad | CA | N/A | N/A

US-CL-CURRENT: 536/24.5; 435/6, 435/91.1, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of Smad4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad4. Methods of using these compounds for modulation of Smad4 expression and for treatment of diseases associated with expression of Smad4 are provided.
20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

4. Document ID: US 6010906 A
Entry 4 of 38
File: USPT

Jan 4, 2000

US-PAT-NO: 6010906
DOCUMENT-IDENTIFIER: US 6010906 A

TITLE: Antisense modulation of Jun N-terminal kinase kinase-1 expression

DATE-ISSUED: January 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ward; Donna T.	San Diego	CA	N/A	N/A
Cowsert; Lex M.	Carlsbad	CA	N/A	N/A

US-CL-CURRENT: 435/375; 435/6, 435/91.1, 435/91.3, 536/23.1, 536/24.1, 536/24.5

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of Jun N-terminal Kinase Kinase-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Jun N-terminal Kinase Kinase-1. Methods of using these compounds for modulation of Jun N-terminal Kinase Kinase-1 expression and for treatment of diseases associated with expression of Jun N-terminal Kinase Kinase-1 are provided.

24 Claims, 0 Drawing figures
Exemplary Claim Number: 1

5. Document ID: US 6008344 A
Entry 5 of 38
File: USPT
Dec 28, 1999

US-PAT-NO: 6008344
DOCUMENT-IDENTIFIER: US 6008344 A

TITLE: Antisense modulation of phospholipase A2 group IV expression

DATE-ISSUED: December 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bennett; C. Frank	Carlsbad	CA	N/A	N/A
Cowsert; Lex M.	Carlsbad	CA	N/A	N/A

US-CL-CURRENT: 536/24.5; 435/325, 435/6, 435/91.1, 435/91.31, 536/23.1, 536/23.2, 536/24.3

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of Phospholipase A2 Group IV. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phospholipase A2 Group IV. Methods of using these compounds for modulation of Phospholipase A2 Group IV expression and for treatment of diseases associated with expression of Phospholipase A2 Group IV are provided.

20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

6. Document ID: US 6008048 A
Entry 6 of 38
File: USPT
Dec 28, 1999

US-PAT-NO: 6008048
DOCUMENT-IDENTIFIER: US 6008048 A

TITLE: Antisense inhibition of EGR-1 expression

DATE-ISSUED: December 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Monia; Brett P.	La Costa	CA	N/A	N/A
Cowsert; Lex M.	Carlsbad	CA	N/A	N/A

US-CL-CURRENT: 435/375; 435/366, 435/6, 435/91.1, 536/23.1, 536/24.31, 536/24.33, 536/24.5

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of EGR-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EGR-1. Methods of using these compounds for modulation of EGR-1 expression and for treatment of diseases associated with expression of EGR-1 are provided.

10 Claims, 0 Drawing figures
Exemplary Claim Number: 1

7. Document ID: US 5998206 A
Entry 7 of 38
File: USPT
Dec 7, 1999

US-PAT-NO: 5998206
DOCUMENT-IDENTIFIER: US 5998206 A

TITLE: Antisense inhibiton of human G-alpha-12 expression

DATE-ISSUED: December 7, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cowsert; Lex M.	Carlsbad	CA	N/A	N/A

US-CL-CURRENT: 435/375; 435/325, 435/366, 435/455, 435/6, 435/91.1, 536/23.1, 536/24.3, 536/24.31, 536/24.33, 536/24.5

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-12. Methods of using these compounds for modulation of G-alpha-12 expression and for treatment of diseases associated with expression of G-alpha-12 are provided.
10 Claims, 0 Drawing figures
Exemplary Claim Number: 1

8. Document ID: US 5998148 A
Entry 8 of 38
File: USPT
Dec 7, 1999

US-PAT-NO: 5998148
DOCUMENT-IDENTIFIER: US 5998148 A

TITLE: Antisense modulation of microtubule-associated protein 4 expression

DATE-ISSUED: December 7, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bennett; C. Frank	Carlsbad	CA	N/A	N/A
Ackermann; Elizabeth J.	Solana Beach	CA	N/A	N/A

US-CL-CURRENT: 435/6; 435/325, 536/24.5

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of microtubule-associated protein 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding microtubule-associated protein 4. Methods of using these compounds for modulation of microtubule-associated protein 4 expression and for treatment of diseases associated with expression of microtubule-associated protein 4 are provided.
14 Claims, 0 Drawing figures
Exemplary Claim Number: 1

9. Document ID: US 5985664 A
Entry 9 of 38
File: USPT
Nov 16, 1999

US-PAT-NO: 5985664
DOCUMENT-IDENTIFIER: US 5985664 A

TITLE: Antisense modulation of Sentrin expression

DATE-ISSUED: November 16, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baker; Brenda F.	Carlsbad	CA	N/A	N/A
Cowsert; Lex M.	Carlsbad	CA	N/A	N/A

US-CL-CURRENT: 435/375; 435/366, 435/6, 435/91.1, 536/23.1, 536/24.31, 536/24.33, 536/24.5

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of Sentrin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Sentrin. Methods of using these compounds for modulation of Sentrin expression and for treatment of diseases associated with expression of Sentrin are provided.
12 Claims, 0 Drawing figures
Exemplary Claim Number: 1

10. Document ID: US 5985663 A
Entry 10 of 38
File: USPT
Nov 16, 1999

US-PAT-NO: 5985663
DOCUMENT-IDENTIFIER: US 5985663 A

TITLE: Antisense inhibition of interleukin-15 expression

DATE-ISSUED: November 16, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE

ZIP CODE
COUNTRY

Bennett; C. Frank
Carlsbad
CA
N/A
N/A

Cowsert; Lex M.
Carlsbad
CA
N/A
N/A

US-CL-CURRENT: 435/375; 435/366, 435/6, 435/91.1, 536/23.1, 536/24.31, 536/24.33, 536/24.5

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of Interleukin-15. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interleukin-15. Methods of using these compounds for modulation of Interleukin-15 expression and for treatment of diseases associated with expression of Interleukin-15 are provided.
19 Claims, 0 Drawing figures
Exemplary Claim Number: 1

11. Document ID: US 5981732 A
Entry 11 of 38
File: USPT
Nov 9, 1999

US-PAT-NO: 5981732
DOCUMENT-IDENTIFIER: US 5981732 A

TITLE: Antisense modulation of G-alpha-13 expression

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:
NAME
CITY
STATE
ZIP CODE
COUNTRY

Cowsert; Lex M.
Carlsbad
CA
N/A
N/A

US-CL-CURRENT: 536/24.5; 435/375, 435/6, 536/23.1, 536/24.1, 536/24.3

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-13. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-13. Methods of using these compounds for modulation of G-alpha-13 expression and for treatment of diseases associated with expression of G-alpha-13 are provided.
24 Claims, 0 Drawing figures
Exemplary Claim Number: 1

12. Document ID: US 5977341 A
Entry 12 of 38
File: USPT
Nov 2, 1999

US-PAT-NO: 5977341
DOCUMENT-IDENTIFIER: US 5977341 A

TITLE: Antisense modulation of inhibitor-kappa B kinase-beta expression

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:
NAME
CITY
STATE
ZIP CODE
COUNTRY

Monia; Brett P.
La Costa
CA
N/A
N/A

Cowsert; Lex M.
Carlsbad
CA
N/A
N/A

US-CL-CURRENT: 536/24.5; 435/375, 435/440, 435/6, 435/91.1, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of Inhibitor-kappa B Kinase-beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Inhibitor-kappa B Kinase-beta. Methods of using these compounds for modulation of Inhibitor-kappa B Kinase-beta expression and for treatment of diseases associated with expression of Inhibitor-kappa B Kinase-beta are provided.
19 Claims, 0 Drawing figures
Exemplary Claim Number: 1

13. Document ID: US 5962673 A
Entry 13 of 38
File: USPT
Oct 5, 1999

US-PAT-NO: 5962673
DOCUMENT-IDENTIFIER: US 5962673 A

TITLE: Antisense modulation of inhibitor-kappa B kinase-alpha expression

DATE-ISSUED: October 5, 1999

INVENTOR-INFORMATION:
NAME
CITY
STATE
ZIP CODE
COUNTRY

Monia; Brett P.
La Costa
CA
N/A
N/A

Cowsert; Lex M.
Carlsbad
CA

N/A

N/A

US-CL-CURRENT: 536/24.5; 435/375, 435/6, 536/23.1, 536/24.1, 536/24.3

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of Inhibitor-kappa B Kinase-alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Inhibitor-kappa B Kinase-alpha. Methods of using these compounds for modulation of Inhibitor-kappa B Kinase-alpha expression and for treatment of diseases associated with expression of Inhibitor-kappa B Kinase-alpha are provided.

20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

14. Document ID: US 5959097 A
Entry 14 of 38
File: USPT
Sep 28, 1999

US-PAT-NO: 5959097
DOCUMENT-IDENTIFIER: US 5959097 A

TITLE: Antisense modulation of MEK2 expression

DATE-ISSUED: September 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Monia; Brett P.	La Costa	CA	N/A	N/A
Cowsert; Lex M.	Carlsbad	CA	N/A	N/A

US-CL-CURRENT: 536/24.5; 435/375, 435/6, 536/23.1, 536/24.1, 536/24.3

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of MEK2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEK2. Methods of using these compounds for modulation of MEK2 expression and for treatment of diseases associated with expression of MEK2 are provided.

20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

15. Document ID: US 5958773 A
Entry 15 of 38
File: USPT

US-PAT-NO: 5958773
DOCUMENT-IDENTIFIER: US 5958773 A

TITLE: Antisense modulation of AKT-1 expression

DATE-ISSUED: September 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Monia; Brett P.	La Costa	CA	N/A	N/A
Cowsert; Lex M.	Carlsbad	CA	N/A	N/A

US-CL-CURRENT: 435/375; 435/366, 435/6, 435/91.1, 536/23.1, 536/24.31, 536/24.33, 536/24.5

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of Akt-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Akt-1. Methods of using these compounds for modulation of Akt-1 expression and for treatment of diseases associated with expression of Akt-1 are provided.

12 Claims, 0 Drawing figures
Exemplary Claim Number: 1

16. Document ID: US 5958772 A
Entry 16 of 38
File: USPT
Sep 28, 1999

US-PAT-NO: 5958772
DOCUMENT-IDENTIFIER: US 5958772 A

TITLE: Antisense inhibition of cellular inhibitor of apoptosis-1 expression

DATE-ISSUED: September 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bennett; C. Frank	Carlsbad	CA	N/A	N/A
Ackermann; Elizabeth J.	Solana Beach	CA	N/A	N/A
Cowsert; Lex M.	Carlsbad	CA	N/A	

N/A

US-CL-CURRENT: 435/375; 435/325, 435/366, 435/6, 435/91.1, 536/23.1, 536/24.31, 536/24.33

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of
Cellular Inhibitor of Apoptosis-1. The compositions comprise antisense compounds, particularly
antisense oligonucleotides, targeted to nucleic acids encoding Cellular Inhibitor of Apoptosis-1.
Methods of using these compounds for modulation of Cellular Inhibitor of Apoptosis-1 expression
and for treatment of diseases associated with expression of Cellular Inhibitor of Apoptosis-1 are
provided.
12 Claims, 0 Drawing figures
Exemplary Claim Number: 1

17. Document ID: US 5958771 A
Entry 17 of 38
File: USPT
Sep 28, 1999

US-PAT-NO: 5958771
DOCUMENT-IDENTIFIER: US 5958771 A

TITLE: Antisense modulation of cellular inhibitor of Apoptosis-2 expression

DATE-ISSUED: September 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bennett; C. Frank	Carlsbad	CA	N/A	N/A
Ackermann; Elizabeth J.	Solana Beach	CA	N/A	N/A
Cowsert; Lex M.	Carlsbad	CA	N/A	N/A

US-CL-CURRENT: 435/375; 435/366, 435/6, 435/91.1, 536/23.1, 536/24.31, 536/24.33, 536/24.5

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of
Cellular Inhibitor of Apoptosis-2. The compositions comprise antisense compounds, particularly
antisense oligonucleotides, targeted to nucleic acids encoding Cellular Inhibitor of Apoptosis-2.
Methods of using these compounds for modulation of Cellular Inhibitor of Apoptosis-2 expression
and for treatment of diseases associated with expression of Cellular Inhibitor of Apoptosis-2 are
provided.
12 Claims, 0 Drawing figures

Exemplary Claim Number: 1

18. Document ID: US 5951455 A
Entry 18 of 38
File: USPT
Sep 14, 1999

US-PAT-NO: 5951455
DOCUMENT-IDENTIFIER: US 5951455 A

TITLE: Antisense modulation of G-alpha-11 expression

DATE-ISSUED: September 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cowsert; Lex M.	Carlsbad	CA	N/A	N/A

US-CL-CURRENT: 435/375; 435/366, 435/6, 435/91.1, 536/23.1, 536/24.31, 536/24.33, 536/24.5

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of
G-alpha-11. The compositions comprise antisense compounds, particularly antisense
oligonucleotides, targeted to nucleic acids encoding G-alpha-11. Methods of using these compounds
for modulation of G-alpha-11 expression and for treatment of diseases associated with expression
of G-alpha-11 are provided.
12 Claims, 0 Drawing figures
Exemplary Claim Number: 1

19. Document ID: US 5948680 A
Entry 19 of 38
File: USPT
Sep 7, 1999

US-PAT-NO: 5948680
DOCUMENT-IDENTIFIER: US 5948680 A

TITLE: Antisense inhibition of Elk-1 expression

DATE-ISSUED: September 7, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baker; Brenda F.	Carlsbad	CA	N/A	N/A
Cowsert; Lex M.	Carlsbad	CA	N/A	N/A

US-CL-CURRENT: 435/375; 435/325, 435/366, 435/6, 435/91.1, 536/23.1, 536/24.31, 536/24.33, 536/24.5

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of ELK-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ELK-1. Methods of using these compounds for modulation of ELK-1 expression and for treatment of diseases associated with expression of ELK-1 are provided.

12 Claims, 0 Drawing figures
Exemplary Claim Number: 1

20. Document ID: US 5935994 A
Entry 20 of 38
File: USPT
Aug 10, 1999

US-PAT-NO: 5935994
DOCUMENT-IDENTIFIER: US 5935994 A

TITLE: Nutritionally balanced dermal composition and method

DATE-ISSUED: August 10, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nimni; Marcel E.	Santa Monica	CA	90405	N/A

US-CL-CURRENT: 514/458; 514/474, 514/561, 514/562

ABSTRACT:

A composition and method for enhancing the appearance of the skin, the composition containing a mixture of essential amino acids, a penetrant, a neucleotide, vitamin C and vitamin E.

6 Claims, 0 Drawing figures
Exemplary Claim Number: 1

21. Document ID: US 5916910 A
Entry 21 of 38
File: USPT
Jun 29, 1999

US-PAT-NO: 5916910
DOCUMENT-IDENTIFIER: US 5916910 A

TITLE: Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore

DATE-ISSUED: June 29, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lai; Ching-San	Encinitas	CA	N/A	N/A

US-CL-CURRENT: 514/423; 514/514, 548/564, 548/573, 558/235

ABSTRACT:

In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

27 Claims, 0 Drawing figures
Exemplary Claim Number: 1

22. Document ID: US 5879713 A
Entry 22 of 38
File: USPT
Mar 9, 1999

US-PAT-NO: 5879713
DOCUMENT-IDENTIFIER: US 5879713 A

TITLE: Targeted delivery via biodegradable polymers

DATE-ISSUED: March 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roth; Laurence A.	Windham	NH	N/A	N/A
Herman; Stephen Jack	Andover	MA	N/A	N/A

US-CL-CURRENT: 424/489; 424/423, 424/501, 514/2, 514/21, 514/824, 514/964, 514/965

ABSTRACT:

Delivery of bioactive molecules such as nucleic acid molecules encoding a protein can be significantly enhanced by immobilization of the bioactive molecule in a polymeric material adjacent to the cells where delivery is desired, where the bioactive molecule is encapsulated in

a vehicle such as liposomes which facilitates transfer of the bioactive molecules into the
targeted tissue. Targeting of the bioactive molecules can also be achieved by selection of an
encapsulating medium of an appropriate size whereby the medium serves to deliver the molecules to
a particular target. For example, encapsulation of nucleic acid molecules or biologically active
proteins within biodegradable, biocompatible polymeric microparticles which are appropriate sized
to infiltrate, but remain trapped within, the capillary beds and alveoli of the lungs can be used
for targeted delivery to these regions of the body following administration to a patient by
infusion or injection.
13 Claims, 0 Drawing figures
Exemplary Claim Number: 1

23. Document ID: US 5693769 A
Entry 23 of 38
File: USPT
Dec 2, 1997

US-PAT-NO: 5693769
DOCUMENT-IDENTIFIER: US 5693769 A

TITLE: Glycosylated steroid derivatives for transport across biological membranes and process for
making and using same

DATE-ISSUED: December 2, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kahne; Daniel Evan	Princeton	NJ	N/A	N/A
Kahne; Suzanne Walker	Princeton	NJ	N/A	N/A

US-CL-CURRENT: 536/5

ABSTRACT:

Novel glycosylated steroid derivatives for facilitating the transport of compounds across
biological membranes, either in admixture or as conjugates, are disclosed. A novel process for
efficient synthesis of these glycosylated steroid derivatives, using activated glycosyl sulfoxide
intermediates is provided. Methods for the permeabilization of membranes and the enhancement of
the activity of predetermined compounds are also provided.
6 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

24. Document ID: US 5627270 A
Entry 24 of 38
File: USPT
May 6, 1997

US-PAT-NO: 5627270
DOCUMENT-IDENTIFIER: US 5627270 A

TITLE: Glycosylated steroid derivatives for transport across biological membranes and process for
making and using same

DATE-ISSUED: May 6, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kahne; Daniel E.	Princeton	NJ	N/A	N/A
Kahne; Suzanne W.	Princeton	NJ	N/A	N/A
Sofia; Michael J.	Laurenceville	NJ	N/A	N/A
Hatzenbuhler; Nicole T.	Kendall Park	NJ	N/A	N/A

US-CL-CURRENT: 536/5; 536/23.1, 536/24.1, 536/24.3

ABSTRACT:

Novel glycosylated steroid derivatives for facilitating the transport of compounds across
biological membranes, either in admixture or as conjugates, are disclosed. A novel process for
efficient synthesis of these glycosylated steroid derivatives, using activated glycosyl sulfoxide
intermediates is provided. Methods for the permeabilization of membranes and the enhancement of
the activity of predetermined compounds are also provided.
7 Claims, 22 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 22

25. Document ID: US 5510396 A
Entry 25 of 38
File: USPT
Apr 23, 1996

US-PAT-NO: 5510396
DOCUMENT-IDENTIFIER: US 5510396 A

TITLE: Process for producing flowable osteogenic composition containing demineralized bone
particles

DATE-ISSUED: April 23, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Prewett; Annamarie B.				

Little Silver
NJ
N/A
N/A
Stikeleather; Roger C.
Doylestown
PA
N/A
N/A

US-CL-CURRENT: 523/113; 424/422, 523/114, 523/115, 623/16

ABSTRACT:

Demineralized bone particles having a median length to median thickness ratio of at least about
10:1 are incorporated in an osteogenic composition useful for repairing bone defects.
20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

26. Document ID: US 5507813 A
Entry 26 of 38
File: USPT
Apr 16, 1996

US-PAT-NO: 5507813
DOCUMENT-IDENTIFIER: US 5507813 A

TITLE: Shaped materials derived from elongate bone particles

DATE-ISSUED: April 16, 1996

INVENTOR-INFORMATION:
NAME
CITY
STATE
ZIP CODE
COUNTRY
Dowd; Michael
Bordentown
NJ
N/A
N/A
Dyke; Denis G.
Long Branch
NJ
N/A
N/A

US-CL-CURRENT: 623/16; 623/11, 623/66

ABSTRACT:

Surgically implantable shaped materials, e.g., sheets, are fabricated from elongate bone
particles, advantageously those that have been demineralized. The materials when applied to a
bone repair site enhance or accelerate new bone ingrowth by any one of a variety of biological
and/or mechanical mechanisms.
21 Claims, 0 Drawing figures
Exemplary Claim Number: 1

27. Document ID: US 5484601 A
Entry 27 of 38
File: USPT
Jan 16, 1996

US-PAT-NO: 5484601
DOCUMENT-IDENTIFIER: US 5484601 A

TITLE: Flowable demineralized bone powder composition and its use in bone repair

DATE-ISSUED: January 16, 1996

INVENTOR-INFORMATION:
NAME
CITY
STATE
ZIP CODE
COUNTRY
O'Leary; Robert K.
Spring Lake
NJ
N/A
N/A
McBrayer; Patrick A.
Yardley
PA
N/A
N/A

US-CL-CURRENT: 424/422; 424/184.1, 424/423, 424/520, 424/549, 424/562, 424/94.1, 514/772.2,
514/772.3, 514/772.6, 514/774, 514/777, 514/778, 514/781, 514/785, 514/801, 514/802

ABSTRACT:

A flowable demineralized bone powder composition is provided for use in surgical bone repair.
13 Claims, 0 Drawing figures
Exemplary Claim Number: 1

28. Document ID: US 5439684 A
Entry 28 of 38
File: USPT
Aug 8, 1995

US-PAT-NO: 5439684
DOCUMENT-IDENTIFIER: US 5439684 A

TITLE: Shaped, swollen demineralized bone and its use in bone repair

DATE-ISSUED: August 8, 1995

INVENTOR-INFORMATION:
NAME
CITY
STATE
ZIP CODE
COUNTRY
Prewett; Annamarie B.
Little Silver
NJ
N/A
N/A
Stikeleather; Roger C.
Doylestown
PA
N/A
N/A
Bogdansky; Simon
Marlboro
NJ
N/A
N/A
O'Leary; Robert K.
Spring Lake
NJ
N/A
N/A

US-CL-CURRENT: 424/422; 424/423, 424/549, 514/777, 623/16

ABSTRACT:

A shaped piece of swollen demineralized bone which can also be plasticized is provided for use in surgical bone repair.
26 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

29. Document ID: US 5414077 A
Entry 29 of 38

File: USPT

May 9, 1995

US-PAT-NO: 5414077
DOCUMENT-IDENTIFIER: US 5414077 A

TITLE: Non-nucleoside linkers for convenient attachment of labels to oligonucleotides using standard synthetic methods

DATE-ISSUED: May 9, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lin; Kuei-Ying	Fremont	CA	N/A	N/A
Matteucci; Mark	Burlingame	CA	N/A	N/A

US-CL-CURRENT: 536/24.3; 435/6, 536/25.32, 546/23

ABSTRACT:

Pseudonucleosides and pseudonucleotides are useful in the synthesis of oligomers which contain these components as a means to derivatize the resulting oligonucleotide to useful substituents such as chelators, intercalators, or lipophilic compounds. In general, these pseudonucleotide components are of the formula: ##STR1## wherein each Y is independently O or S; each X is independently H, PO.sub.3.sup.-2, an activated nucleotide synthesis coupling moiety, a protecting group, a nucleoside, a nucleotide or a nucleotide sequence, or comprises a solid support;

F is a functional group capable of linking an additional moiety or said group already reacted to effect the binding of said additional moiety;

.quadrature. is an organic backbone which does not contain additional F or Y-X substituents and which is either achiral even when the Y-X substituents are different, or is a single enantiomer of a chiral compound;

with the proviso that at least one X is a nucleoside, nucleotide, nucleotide sequence, an activated nucleotide synthesis coupling moiety, or comprises a solid support, or F represents said functional group already reacted with an additional group. Oligonucleotides having the pseudonucleoside at the 3' terminus are particularly stable in vivo.
9 Claims, 0 Drawing figures
Exemplary Claim Number: 1

30. Document ID: US 5405390 A
Entry 30 of 38

File: USPT

Apr 11, 1995

US-PAT-NO: 5405390
DOCUMENT-IDENTIFIER: US 5405390 A

TITLE: Osteogenic composition and implant containing same

DATE-ISSUED: April 11, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Leary; Robert K.	Spring Lake	NJ	N/A	N/A
Prewett; Annamarie B.	Little Silver	NJ	N/A	N/A

US-CL-CURRENT: 623/16

ABSTRACT:

An osteogenic composition is obtained from demineralized bone tissue.
32 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

31. Document ID: US 5314476 A
Entry 31 of 38

File: USPT

May 24, 1994

US-PAT-NO: 5314476
DOCUMENT-IDENTIFIER: US 5314476 A

TITLE: Demineralized bone particles and flowable osteogenic composition containing same

DATE-ISSUED: May 24, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Prewett; Annamarie B.	Little Silver	NJ	N/A	N/A
Stikeleather; Roger C.	Doylestown	PA		

N/A
N/A

US-CL-CURRENT: 623/16; 424/422, 424/423, 623/11, 623/18

ABSTRACT:

Demineralized bone particles having a median length to median thickness ratio of at least about
10:1 are incorporated in an osteogenic composition useful for repairing bone defects.
20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

32. Document ID: US 5298254 A
Entry 32 of 38
File: USPT
Mar 29, 1994

US-PAT-NO: 5298254
DOCUMENT-IDENTIFIER: US 5298254 A

TITLE: Shaped, swollen demineralized bone and its use in bone repair

DATE-ISSUED: March 29, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Prewett; Annamarie B.	Little Silver	NJ	N/A	N/A
Stikeleather; Roger C.	Doylestown	PA	N/A	N/A
Bogdansky; Simon	Marlboro	NJ	N/A	N/A
O'Leary; Robert K.	Spring Lake	NJ	N/A	N/A

US-CL-CURRENT: 424/422; 424/423, 424/549, 514/772.3, 514/777, 514/779, 514/780, 514/785, 514/801, 514/802, 514/953, 623/16

ABSTRACT:

A shaped piece of swollen demineralized bone which can also be plasticized is provided for use in
surgical bone repair.
30 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

33. Document ID: US 5290558 A
Entry 33 of 38
File: USPT
Mar 1, 1994

US-PAT-NO: 5290558
DOCUMENT-IDENTIFIER: US 5290558 A

TITLE: Flowable demineralized bone powder composition and its use in bone repair

DATE-ISSUED: March 1, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Leary; Robert K.	Spring Lake	NJ	N/A	N/A
McBrayer; Patrick A.	Yardley	PA	N/A	N/A

US-CL-CURRENT: 424/422; 424/423, 424/549, 514/772, 514/777, 623/16

ABSTRACT:

A flowable demineralized bone powder composition is provided for use in surgical bone repair.
21 Claims, 0 Drawing figures
Exemplary Claim Number: 1

34. Document ID: US 5236456 A
Entry 34 of 38
File: USPT
Aug 17, 1993

US-PAT-NO: 5236456
DOCUMENT-IDENTIFIER: US 5236456 A

TITLE: Osteogenic composition and implant containing same

DATE-ISSUED: August 17, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Leary; Robert K.	Spring Lake	NJ	N/A	N/A
Prewett; Annamarie B.	Little Silver	NJ	N/A	N/A

US-CL-CURRENT: 623/16; 128/DIG.8, 424/422, 623/18

ABSTRACT:

An osteogenic composition is obtained from demineralized bone tissue.
28 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

35. Document ID: US 5073373 A
Entry 35 of 38
File: USPT
Dec 17, 1991

US-PAT-NO: 5073373
DOCUMENT-IDENTIFIER: US 5073373 A

TITLE: Flowable demineralized bone powder composition and its use in bone repair

DATE-ISSUED: December 17, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Leary; Robert K.	Spring Lake	NJ	N/A	N/A
McBrayer; Patrick A.	Yardley	PA	N/A	N/A

US-CL-CURRENT: 424/422; 424/423, 424/549, 424/94.1, 514/785, 514/801, 514/802, 623/16

ABSTRACT:

A flowable demineralized bone powder composition is provided for use in surgical bone repair.
14 Claims, 0 Drawing figures
Exemplary Claim Number: 1

36. Document ID: US 5061286 A
Entry 36 of 38
File: USPT
Oct 29, 1991

US-PAT-NO: 5061286
DOCUMENT-IDENTIFIER: US 5061286 A

TITLE: Osteoprosthetic implant

DATE-ISSUED: October 29, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lyle; John W.	Belmar	NJ	N/A	N/A

US-CL-CURRENT: 623/16; 623/23, 623/66

ABSTRACT:

At least a portion of the surface of an osteoprosthetic implant is provided with demineralized
bone powder adhering thereto. Sorption of the bone particles is accompanied by rapid and deep
bone in-growth which firmly anchors the prosthesis to the host bone repair site.
19 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

37. Document ID: AU 9883786 A, WO 9901579 A1
Entry 37 of 38
File: DWPI
Jan 25, 1999

DERWENT-ACC-NO: 1999-106077
DERWENT-WEEK: 199923

TITLE: Composition comprising nucleic acid and penetration enhancer - used particularly for
delivering therapeutic antisense oligonucleotides across the gastrointestinal mucosa, provides
high bioavailability
INVENTOR: HARDEE, G; TENG, C

PRIORITY-DATA:
1997US-0886829
July 1, 1997

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 9883786 A	January 25, 1999	N/A	000	C12Q001/68
WO 9901579 A1	January 14, 1999	E	114	C12Q001/68

INT-CL (IPC): A61K 9/127; A61K 48/00; C07H 21/04; C12Q 1/68

ABSTRACTED-PUB-NO: WO 9901579A
BASIC-ABSTRACT:

Composition comprises a nucleic acid (I) and at least one penetration enhancer (II).

USE - The compositions are used: (i) to treat or prevent any disease or disorder that can be
treated with (I), e.g. cancer, Alzheimer's disease, beta -thalassemia, malaria, viral infections
(including human immune deficiency virus (HIV)), inflammation etc., in human or animal medicine;
(ii) to investigate the role of a gene or gene product in non-human animals, and (iii) to
modulate gene expression in cells, tissues or organs.

ADVANTAGE - The compositions provide bioavailability of at least 15, preferably 17-35,%. (II)
improves: (i) transport of (I) across the mucosa of the alimentary canal and into cells, and (ii)
increases stability of (I). Oral administration avoids the complications and expense of
intravenous or other methods of administration.

38. Document ID: WO 9113080 A, AU 9175799 A, US 5414077 A

Entry 38 of 38

File: DWPI

Sep 5, 1991

DERWENT-ACC-NO: 1991-281412
DERWENT-WEEK: 199138

TITLE: New pseudo-nucleotide(s), pseudo-nucleoside(s) and their polymers - useful in anti-sense
therapy and can be modified to enhance exo-nuclease stability, specific binding to DNA or RNA
targets, etc.
INVENTOR: LIN, K; MATTEUCCI, M ; LIN, K Y

PRIORITY-DATA:
1990US-0594147
October 9, 1990
1990US-0482943
February 20, 1990
1994US-0237233
May 2, 1994

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9113080 A	September 5, 1991	N/A	000	N/A
AU 9175799 A	September 18, 1991	N/A	000	N/A
US 5414077 A	May 9, 1995	N/A	013	C07H021/04

INT-CL (IPC): A61K 31/70; C07H 17/00; C07H 21/04

ABSTRACTED-PUB-NO: US 5414077A
BASIC-ABSTRACT:

Pseudonucleosides and pseudonucleotides of formula (I) are new. Y = O or S. X = H, PO3(-2), an
activated nucleotide synthesis coupling moiety, a protecting gp. a nucleoside, a nucleotide or
nucleotide sequence, or comprises a solid support.

F is a functional gp. which is either bound to an additional moiety or is capable of binding to
it. The square denotes an organic backbone which does not contain F or Y-X substits. and which is
either achiral or is a single enantiomer. Either at least one X is a nucleoside, nucleotide,
nucleotide sequence, an activated nucleotide synthesis coupling moeity or is a solid support; or
when both X = H, the functional gp. F is derivatised to a reporter gp. oligonucleotide cleavage
or binding agent, membrane penetration enhancer, oligonucleotide cross-linking agent or
protecting gp.

(I) is e.g. XY-(CH2)n-N(F)-(CH2)n-YX, where n = 1-10. F is e.g. ethyl, cholesteryl, acridine,
anthraquinone or rhodamine.

USE/ADVANTAGE - (I) (when at least one X is a nucleotide sequence) are useful in diagnostics and
for treating diseases mediated by polynucleotides or proteins. They can be utilised in antisense
therapy, since they are able to inactivate certain target DNA, RNA or protein sequences.
Modifications may be made at the 3' terminus of (I) to enhance in vivo stability to exonucleases.
These modifications do not interfere with activity. Other desirable properties that may be
conferred include enhanced specific binding to DNA or RNA targets, permeation into cells and
resistance to renal clearance. Injection is the pref. route of admin. but (I) can also be given
orally, transmucosally, transdermally or topically.
ABSTRACTED-PUB-NO:

WO 9113080A EQUIVALENT-ABSTRACTS:

Cpds. of formula (I) are new. n = 1-10, Y - O or S. One X = a nucleotide, nucleotide,
oligonucleotide, activated nucleotide synthesis coupling agent and a solid support linked to Y
and the other is HPO3/2-, a protecting gp., a nucleoside, nucleotide or oligonucleotide. F' = a
functional linker or gp. e.g. a reporter, oligonucleotide cleavage entity, oligonucleotide
binding agent, membrane penetration enhancer, oligonucleotide crosslinking agent or protecting
gp.

USE - For forming oligomers to be used in diagnosis.

Term	Documents
2 SAME 4	38

including document number

Display Format: